# Commission Delegated Regulation (EU) 2020/689 of 17 December 2019 supplementing Regulation (EU) 2016/429 of the European Parliament and of the Council as regards rules for surveillance, eradication programmes, and disease-free status for certain listed and emerging diseases (Text with EEA relevance), Section 5: Infection with Aujeszky’s disease virus (ADV)

Extent: E+W+S+N.I.

ELISA for the detection of antibodies against whole ADV, ADV-gB protein or ADV-gD protein. For batch control of ADV-gB kits and ADV-gD kits or whole ADV kits, Community reference serum ADV 1, or sub-standards, must be scored positive at the dilution of 1:2. When referred to tests for the detection of whole ADV in Part V of Annex IV either of these tests may be used.
ELISA for the detection of antibodies against ADV-gE protein. For batch control, Community reference serum ADV 1, or sub-standards, must be scored positive at the dilution 1:8.
Methods:
Matrix:
non-vaccinated porcine animals
ADV ELISA
individual or up to 5 pooled serum (or plasma) samples
individual or up to 5 pooled filter paper samples
individual meat juice samples
DIVA vaccinated porcine animals with a gE-deleted vaccine
gE ELISA
individual serum samples

---
Source: https://www.legislation.gov.uk/eur/2020/689/annex/III/section/5 (the official version)
Page: https://openlegislation.uk/eu-regulation-2020-689/annex-III/section-5
Contains public sector information licensed under the Open Government Licence v3.0. Source: legislation.gov.uk, The National Archives.